"Prostatism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lower urinary tract symptom, such as slow urinary stream, associated with PROSTATIC HYPERPLASIA in older men.
| Descriptor ID |
D053448
|
| MeSH Number(s) |
C23.888.942.343.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Prostatism".
Below are MeSH descriptors whose meaning is more specific than "Prostatism".
This graph shows the total number of publications written about "Prostatism" by people in this website by year, and whether "Prostatism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostatism" by people in Profiles.
-
Murphy A, Teplitsky S, Das AK, Leong JY, Margules A, Lallas CD. Medical evaluation and management of male and female voiding dysfunction: a review. Rom J Intern Med. 2019 Sep 01; 57(3):220-232.
-
Roehrborn CG, Teplitsky S, Das AK. Aquablation of the prostate: a review and update. Can J Urol. 2019 08; 26(4 Suppl 1):20-24.
-
Das AK, Teplitsky S, Humphreys MR. Holmium laser enucleation of the prostate (HoLEP): a review and update. Can J Urol. 2019 08; 26(4 Suppl 1):13-19.
-
Sandhu JS, Leong JY, Das AK. Photoselective vaporization of the prostate: application, outcomes and safety. Can J Urol. 2019 08; 26(4 Suppl 1):8-12.
-
Das AK, Leong JY, Roehrborn CG. Office-based therapies for benign prostatic hyperplasia: a review and update. Can J Urol. 2019 08; 26(4 Suppl 1):2-7.
-
Shore N, Tutrone R, Efros M, Bidair M, Wachs B, Kalota S, Freedman S, Bailen J, Levin R, Richardson S, Kaminetsky J, Snyder J, Shepard B, Goldberg K, Hay A, Gange S, Grunberger I. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol. 2018 May; 36(5):801-809.
-
Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Herron S, Rashid P, Rukstalis DB. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017 Jun; 24(3):8802-8813.
-
Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rashid P. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol. 2015 Jun; 22(3):7772-82.